PL2575872T3 - Zatężanie antygenów szczepionkowych grypy bez liofilizacji - Google Patents

Zatężanie antygenów szczepionkowych grypy bez liofilizacji

Info

Publication number
PL2575872T3
PL2575872T3 PL11743338.3T PL11743338T PL2575872T3 PL 2575872 T3 PL2575872 T3 PL 2575872T3 PL 11743338 T PL11743338 T PL 11743338T PL 2575872 T3 PL2575872 T3 PL 2575872T3
Authority
PL
Poland
Prior art keywords
lyophilization
concentration
influenza vaccine
vaccine antigens
antigens
Prior art date
Application number
PL11743338.3T
Other languages
English (en)
Inventor
Sushma Kommareddy
Amanda Scampini
Barbara Baudner
Derek O'hagan
Manmohan Singh
Original Assignee
Seqirus UK Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seqirus UK Limited filed Critical Seqirus UK Limited
Publication of PL2575872T3 publication Critical patent/PL2575872T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Surgical Instruments (AREA)
PL11743338.3T 2010-06-01 2011-06-01 Zatężanie antygenów szczepionkowych grypy bez liofilizacji PL2575872T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39671910P 2010-06-01 2010-06-01
US201161465405P 2011-03-18 2011-03-18
PCT/IB2011/001542 WO2011151723A2 (en) 2010-06-01 2011-06-01 Concentration of vaccine antigens without lyophilization

Publications (1)

Publication Number Publication Date
PL2575872T3 true PL2575872T3 (pl) 2021-02-22

Family

ID=45067143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11743338.3T PL2575872T3 (pl) 2010-06-01 2011-06-01 Zatężanie antygenów szczepionkowych grypy bez liofilizacji

Country Status (15)

Country Link
US (1) US20130224245A1 (pl)
EP (2) EP3827843A1 (pl)
JP (1) JP5959508B2 (pl)
KR (5) KR20130109004A (pl)
CN (1) CN103096921A (pl)
AU (1) AU2011262309B2 (pl)
BR (1) BR112012030619A2 (pl)
CA (1) CA2801149A1 (pl)
DK (1) DK2575872T3 (pl)
EA (1) EA201291437A1 (pl)
ES (1) ES2825712T3 (pl)
HU (1) HUE051711T2 (pl)
PL (1) PL2575872T3 (pl)
PT (1) PT2575872T (pl)
WO (1) WO2011151723A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
TR201807340T4 (tr) * 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
WO2017005880A1 (en) * 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
WO2017062463A1 (en) * 2015-10-05 2017-04-13 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US11628208B2 (en) * 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
JP7089479B2 (ja) * 2016-04-14 2022-06-22 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 抗菌性ポリアミド又はオクテニジン保存剤を含むマルチドーズ組成物
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
AU2019391791A1 (en) * 2018-12-03 2021-06-03 Eirion Therapeutics, Inc. Improved delivery of large agents
CA3150482A1 (en) 2019-09-16 2021-03-25 Amgen Inc. Method for external sterilization of drug delivery device
KR20250171641A (ko) 2024-05-30 2025-12-09 경희대학교 산학협력단 구강 용해 필름 제형의 바이러스 백신 조성물

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
EP0582581B1 (en) 1991-03-01 1999-05-06 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
CA2180965C (en) 1994-01-11 2010-05-11 Tom Maria Deroo Influenza vaccine
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
AU7126998A (en) 1997-04-16 1998-11-11 Connaught Laboratories Inc. Anti-influenza compositions supplemented with neuraminidase
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AR025750A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
WO2001064846A1 (fr) 2000-03-03 2001-09-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2003004341A1 (fr) 2001-06-30 2003-01-16 Haiyue Zhang Bicyclette multifonction permettant de faire de l'exercice et de la gymnastique
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
AR040819A1 (es) * 2002-08-08 2005-04-20 Alza Corp Dispositivo de administracion transdermica de vacuna que tiene microproyecciones revestidas
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
CA2562932A1 (en) * 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
WO2005112463A2 (en) * 2004-05-19 2005-11-24 Alza Corporation Method and formulation for transdermal delivery of immunologically active agents
US20080254067A1 (en) 2004-05-20 2008-10-16 Id Biomedical Corporation Process for the Production of an Influenza Vaccine
PL2236155T3 (pl) 2004-09-09 2012-10-31 Novartis Ag Zmniejszenie potencjalnego zagrożenia jatrogennego związanego ze szczepionkami przeciwko grypie
CN103555670B (zh) 2004-12-23 2015-08-12 米迪缪尼有限公司 用于病毒增殖的非致瘤性mdck细胞系
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
JP5161776B2 (ja) 2005-09-06 2013-03-13 セラジェクト， インコーポレイテッド 薬物粒子および／または薬物を吸着した粒子を含む、固溶体穿孔器
ES2359214T5 (es) 2005-11-01 2014-10-08 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona
EP1951357A4 (en) 2005-11-18 2012-12-12 3M Innovative Properties Co MICRONADELANTS AND MANUFACTURING METHOD THEREFOR
WO2007061781A1 (en) 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
EP2076312A4 (en) 2006-04-20 2013-09-04 3M Innovative Properties Co SHAPED ITEMS WITH MICRONADEL ARRANGEMENTS
CN101553252A (zh) * 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
MX2009013118A (es) * 2007-06-14 2010-03-04 Crucell Switzerland Ag Vacuna intradermica contra la influenza.
HRP20120790T1 (hr) 2007-06-27 2013-01-31 Novartis Ag Cjepiva protiv influence sa niskom koliäśinom aditiva
US20110305768A1 (en) * 2008-07-01 2011-12-15 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
KR20110056516A (ko) * 2008-09-12 2011-05-30 크리티컬 파머수티컬스 리미티드 점막 또는 피부를 통한 치료제의 흡수 개선
CA2738024A1 (en) * 2008-09-24 2010-04-01 Medimmune, Llc Methods for purification of viruses

Also Published As

Publication number Publication date
EP3827843A1 (en) 2021-06-02
HUE051711T2 (hu) 2021-03-29
PT2575872T (pt) 2020-11-19
KR20130109004A (ko) 2013-10-07
US20130224245A1 (en) 2013-08-29
JP5959508B2 (ja) 2016-08-02
BR112012030619A2 (pt) 2019-09-24
KR20180096829A (ko) 2018-08-29
KR20220163497A (ko) 2022-12-09
EP2575872B1 (en) 2020-08-19
KR20200057097A (ko) 2020-05-25
KR20210154996A (ko) 2021-12-21
CN103096921A (zh) 2013-05-08
AU2011262309B2 (en) 2015-08-13
ES2825712T3 (es) 2021-05-17
WO2011151723A3 (en) 2012-06-07
EA201291437A1 (ru) 2013-05-30
WO2011151723A2 (en) 2011-12-08
CA2801149A1 (en) 2011-12-08
EP2575872A2 (en) 2013-04-10
KR102471356B1 (ko) 2022-11-28
AU2011262309A1 (en) 2012-12-20
DK2575872T3 (da) 2020-10-19
KR102113512B1 (ko) 2020-05-22
JP2013534912A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
PL2575873T3 (pl) Zatężanie i liofilizacja antygenów szczepionkowych grypy
PL2575872T3 (pl) Zatężanie antygenów szczepionkowych grypy bez liofilizacji
IL262123A (en) Influenza virus vaccines and uses thereof
IL261204A (en) Influenza virus vaccines and their use
ZA201404797B (en) Influenza virus vaccines and uses thereof
IL248607A (en) Methods and compositions for immunization against virus
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
DK3170508T3 (da) Vaccineformuleringer
EP2753345A4 (en) POLYPEPTIDIMPFSTOFF
EP2595653A4 (en) INFLUENZA VACCINE
IL229307A0 (en) Inactivated dengue virus vaccine
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
EP2852396A4 (en) INFLUENZA VACCINE CONSTRUCTS
IL224022B (en) Thermally stable influenza vaccine
HUE046858T2 (hu) Vakcina és eljárások campylobacter fertõzés csökkentésére
SMT201700046B (it) Micobatterio ricombinante come vaccino
IL232172A0 (en) Antigen presenting cancer vaccine
EP2588135A4 (en) Nanoemulsion vaccines
EP2771350A4 (en) TOPK PEPTIDES AND VACCINES CONTAINING THEM
EP2543387A4 (en) MUCOSA VACCINE
EP2763699A4 (en) VACCINE
EP2667891A4 (en) COMBINATION VACCINES
EP2919806A4 (en) MTON PEPTIDES AND VACCINES DERIVED FROM GONOCOCCES
CL2015001618A1 (es) Adyuvante de vacunación, preparación y vacunas que lo contienen
IL226068B (en) Tomm34 peptides and vaccines including the same